NORSPAN Buprenorphine Transdermal Patchs for Very-low dose group + NORSPAN Buprenorphine Transdermal Patchs for Lower dose group + NORSPAN Buprenorphine Transdermal Patchs for higher dose group
Pre-clinicalRecruiting 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Autism Spectrum Disorder
Conditions
Autism Spectrum Disorder
Trial Timeline
Jan 1, 2025 → Sep 1, 2026
NCT ID
NCT06772324About NORSPAN Buprenorphine Transdermal Patchs for Very-low dose group + NORSPAN Buprenorphine Transdermal Patchs for Lower dose group + NORSPAN Buprenorphine Transdermal Patchs for higher dose group
NORSPAN Buprenorphine Transdermal Patchs for Very-low dose group + NORSPAN Buprenorphine Transdermal Patchs for Lower dose group + NORSPAN Buprenorphine Transdermal Patchs for higher dose group is a pre-clinical stage product being developed by Shionogi for Autism Spectrum Disorder. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06772324. Target conditions include Autism Spectrum Disorder.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06772324 | Pre-clinical | Recruiting |
Competing Products
20 competing products in Autism Spectrum Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ketamine + Placebo | Roivant Sciences | Phase 1 | 30 |
| Cord Tissue Mesenchymal Stromal Cells | Cryo-Cell | Phase 2 | 44 |
| Suramin Sodium | PaxMedica | Phase 2 | 44 |
| Lurasidone 20 mg daily + Lurasidone + Placebo | Sumitomo Pharma | Phase 3 | 77 |
| Cariprazine + Placebo | AbbVie | Phase 3 | 77 |
| Cariprazine | AbbVie | Phase 1 | 33 |
| Omalizumab Injection [Xolair] | Novartis | Phase 1 | 33 |
| RO7017773 | Roche | Phase 1 | 33 |
| Placebo + RO7017773 | Roche | Phase 2 | 52 |
| Balovaptan | Roche | Phase 1 | 33 |
| Balovaptan | Roche | Phase 1 | 33 |
| Balovaptan + Esomeprazole | Roche | Phase 1 | 33 |
| Placebo + RG7314 | Roche | Phase 2 | 52 |
| Placebo + RO5285119 | Roche | Phase 2 | 52 |
| Balovaptan + Placebo | Roche | Phase 3 | 77 |
| KarXT + KarX-EC + KarXT + KarX-EC Matching Placebo | Bristol Myers Squibb | Phase 3 | 76 |
| Aripiprazole | Bristol Myers Squibb | Phase 2 | 51 |
| KarXT + KarX-EC + KarXT + KarX-EC Matching Placebo | Bristol Myers Squibb | Phase 3 | 76 |
| Brexpiprazole + Placebo | Lundbeck | Phase 3 | 74 |
| Brexpiprazole | Lundbeck | Phase 3 | 74 |